Northwestern University, Chicago, IL, USA.
Top Antivir Med. 2021 Oct-Nov;29(4):407-411.
Individuals with HIV have elevated risks for cardiovascular diseases (CVDs) ranging from myocardial infarction to heart failure. Our understanding of this heightened HIV-associated cardiovascular risk has evolved over the past 2 decades. In the early era of antiretroviral therapy (ART), concern existed that ART was the primary driver of cardiovascular risk. However, it has become increasingly apparent that HIV-related viremia, immune dysregulation, and inflammation are primary drivers of HIV-associated cardiovascular risk, along with traditional cardiovascular risk factors such as tobacco smoking. Indeed, early and effective ART blunts risk for CVDs among individuals with HIV. Despite these improvements in HIV-associated cardiovascular risk, questions remain regarding how to optimally predict, prevent, and treat CVDs among individuals with HIV. Efforts are underway to define more precisely which diagnostic and therapeutic strategies will be most effective in curbing HIV-associated CVDs.
HIV 感染者患心血管疾病(CVDs)的风险增加,范围从心肌梗死到心力衰竭。在过去的 20 年中,我们对这种 HIV 相关心血管风险的认识不断发展。在抗逆转录病毒治疗(ART)的早期阶段,人们担心 ART 是心血管风险的主要驱动因素。然而,越来越明显的是,HIV 相关病毒血症、免疫失调和炎症是 HIV 相关心血管风险的主要驱动因素,同时还有传统的心血管危险因素,如吸烟。事实上,早期和有效的 ART 可以降低 HIV 感染者患 CVD 的风险。尽管 HIV 相关心血管风险有所改善,但仍存在如何在 HIV 感染者中最佳预测、预防和治疗 CVD 的问题。目前正在努力更准确地确定哪些诊断和治疗策略最能有效遏制 HIV 相关 CVD。